Y-MABS THERAPEUTICS INC (YMAB) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:YMAB • US9842411095

8.61 USD
+0.02 (+0.23%)
At close: Sep 15, 2025
8.61 USD
0 (0%)
After Hours: 9/15/2025, 8:00:02 PM
Fundamental Rating

4

Taking everything into account, YMAB scores 4 out of 10 in our fundamental rating. YMAB was compared to 524 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for YMAB as it has an excellent financial health rating, but there are worries on the profitability. YMAB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • YMAB had negative earnings in the past year.
  • In the past year YMAB has reported a negative cash flow from operations.
  • YMAB had negative earnings in each of the past 5 years.
  • In the past 5 years YMAB always reported negative operating cash flow.
YMAB Yearly Net Income VS EBIT VS OCF VS FCFYMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • With a decent Return On Assets value of -18.96%, YMAB is doing good in the industry, outperforming 77.59% of the companies in the same industry.
  • The Return On Equity of YMAB (-25.40%) is better than 80.74% of its industry peers.
Industry RankSector Rank
ROA -18.96%
ROE -25.4%
ROIC N/A
ROA(3y)-36.35%
ROA(5y)-45.09%
ROE(3y)-46.99%
ROE(5y)-56.89%
ROIC(3y)N/A
ROIC(5y)N/A
YMAB Yearly ROA, ROE, ROICYMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

  • YMAB has a Gross Margin of 81.78%. This is amongst the best in the industry. YMAB outperforms 85.37% of its industry peers.
  • YMAB's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for YMAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.89%
GM growth 5YN/A
YMAB Yearly Profit, Operating, Gross MarginsYMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • YMAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, YMAB has more shares outstanding
  • YMAB has more shares outstanding than it did 5 years ago.
  • YMAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
YMAB Yearly Shares OutstandingYMAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
YMAB Yearly Total Debt VS Total AssetsYMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 2.71 indicates that YMAB is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • YMAB has a Altman-Z score of 2.71. This is in the better half of the industry: YMAB outperforms 69.81% of its industry peers.
  • YMAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.71
ROIC/WACCN/A
WACC9.9%
YMAB Yearly LT Debt VS Equity VS FCFYMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

  • A Current Ratio of 4.00 indicates that YMAB has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 4.00, YMAB is in line with its industry, outperforming 45.74% of the companies in the same industry.
  • A Quick Ratio of 3.58 indicates that YMAB has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.58, YMAB is in line with its industry, outperforming 43.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4
Quick Ratio 3.58
YMAB Yearly Current Assets VS Current LiabilitesYMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • YMAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.71%, which is quite good.
  • The Revenue has decreased by -1.34% in the past year.
  • YMAB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.95% yearly.
EPS 1Y (TTM)10.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)-1.34%
Revenue growth 3Y35.95%
Revenue growth 5YN/A
Sales Q2Q%-14.36%

3.2 Future

  • YMAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.75% yearly.
  • The Revenue is expected to grow by 17.88% on average over the next years. This is quite good.
EPS Next Y-24.97%
EPS Next 2Y-19.37%
EPS Next 3Y-17.71%
EPS Next 5Y9.75%
Revenue Next Year-5.98%
Revenue Next 2Y3.28%
Revenue Next 3Y6.75%
Revenue Next 5Y17.88%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
YMAB Yearly Revenue VS EstimatesYMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
YMAB Yearly EPS VS EstimatesYMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • YMAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for YMAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YMAB Price Earnings VS Forward Price EarningsYMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YMAB Per share dataYMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • A cheap valuation may be justified as YMAB's earnings are expected to decrease with -17.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.37%
EPS Next 3Y-17.71%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • YMAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

Y-MABS THERAPEUTICS INC

NASDAQ:YMAB (9/15/2025, 8:00:02 PM)

After market: 8.61 0 (0%)

8.61

+0.02 (+0.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08
Earnings (Next)11-06
Inst Owners82.83%
Inst Owner Change-90.04%
Ins Owners0.34%
Ins Owner Change-1015.42%
Market Cap391.24M
Revenue(TTM)85.39M
Net Income(TTM)-22.22M
Analysts53.75
Price Target8.2 (-4.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.27%
Min EPS beat(2)44.37%
Max EPS beat(2)74.16%
EPS beat(4)3
Avg EPS beat(4)25.03%
Min EPS beat(4)-18.84%
Max EPS beat(4)74.16%
EPS beat(8)5
Avg EPS beat(8)16.37%
EPS beat(12)9
Avg EPS beat(12)28.96%
EPS beat(16)10
Avg EPS beat(16)18.43%
Revenue beat(2)2
Avg Revenue beat(2)4.3%
Min Revenue beat(2)4.07%
Max Revenue beat(2)4.54%
Revenue beat(4)2
Avg Revenue beat(4)-4.6%
Min Revenue beat(4)-22.2%
Max Revenue beat(4)4.54%
Revenue beat(8)3
Avg Revenue beat(8)-3.53%
Revenue beat(12)7
Avg Revenue beat(12)4.86%
Revenue beat(16)7
Avg Revenue beat(16)0.93%
PT rev (1m)0%
PT rev (3m)-44.03%
EPS NQ rev (1m)3.14%
EPS NQ rev (3m)22.86%
EPS NY rev (1m)0%
EPS NY rev (3m)18.15%
Revenue NQ rev (1m)0.53%
Revenue NQ rev (3m)0.02%
Revenue NY rev (1m)0.45%
Revenue NY rev (3m)0.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.58
P/FCF N/A
P/OCF N/A
P/B 4.47
P/tB 4.59
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS1.88
BVpS1.93
TBVpS1.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -18.96%
ROE -25.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.78%
FCFM N/A
ROA(3y)-36.35%
ROA(5y)-45.09%
ROE(3y)-46.99%
ROE(5y)-56.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.89%
GM growth 5YN/A
F-Score4
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4
Quick Ratio 3.58
Altman-Z 2.71
F-Score4
WACC9.9%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y-24.97%
EPS Next 2Y-19.37%
EPS Next 3Y-17.71%
EPS Next 5Y9.75%
Revenue 1Y (TTM)-1.34%
Revenue growth 3Y35.95%
Revenue growth 5YN/A
Sales Q2Q%-14.36%
Revenue Next Year-5.98%
Revenue Next 2Y3.28%
Revenue Next 3Y6.75%
Revenue Next 5Y17.88%
EBIT growth 1Y9.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-55.69%
EBIT Next 3Y-14.78%
EBIT Next 5YN/A
FCF growth 1Y60.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.1%
OCF growth 3YN/A
OCF growth 5YN/A

Y-MABS THERAPEUTICS INC / YMAB FAQ

What is the fundamental rating for YMAB stock?

ChartMill assigns a fundamental rating of 4 / 10 to YMAB.


What is the valuation status of Y-MABS THERAPEUTICS INC (YMAB) stock?

ChartMill assigns a valuation rating of 0 / 10 to Y-MABS THERAPEUTICS INC (YMAB). This can be considered as Overvalued.


Can you provide the profitability details for Y-MABS THERAPEUTICS INC?

Y-MABS THERAPEUTICS INC (YMAB) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for YMAB stock?

The Earnings per Share (EPS) of Y-MABS THERAPEUTICS INC (YMAB) is expected to decline by -24.97% in the next year.